Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity

Current Neuropharmacology

Volumn 9, Issue 1, 2011, Pages 40-44

  Dluzen, D E ^a   McDermott, J L ^a   Bourque, M ^b   Di Paolo, T D ^b   Darvesh, A S ^c   Buletko, A B ^a   Laping, N J ^d  

^a Northeast Ohio Medical University   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^d Endo Pharmaceuticals   (United States)

Author keywords

Bcl 2 PAI 1; Body temperature; Body weight; Dopamine transporter; GFAP; IGF 1R

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; METHAMPHETAMINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BCL 2; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BODY WEIGHT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG MECHANISM; FEMALE; MALE; MOUSE; MUTATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN BINDING; PROTEIN DETERMINATION; SEX DIFFERENCE;

EID: 79953032197     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015911795017399     Document Type: Article

References (21)

1. Dluzen, D.E.; McDermott, J.L. Sex differences in dopamine- and vesicular monoamine-transporter functions Implications for methamphetamine use and neurotoxicity. Ann. N.Y. Acad. Sci., 2008, 1139, 140-150.
2. Dluzen, D.E.; Tweed, C.; Anderson, L.I.; Laping, N.J. Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system. Neuroendocrinology, 2003, 77, 232-238.
3. Wagner, G.C.; Tekirian, T.L.; Cheo, C.T. Sexual differences in sensitivity to methamphetamine toxicity. J. Neural Transm. Gen. Sect., 1993, 93, 67-70.
4. Munro, C.A.; McCaul, M.E.; Wong, D.F.; Oswald, L.M.; Zhou, Y.; Brasic, J.; Kuwabara, H.; Kumar, A.; Alexander, M.; Ye, W.; Wand, G.S. Sex differences in striatal dopamine release in healthy adults. Biol. Psychiatry, 2006, 59, 966-974.
5. Hall, J.N.; Broderick, P.M. Community networks for response to abuse outbreaks of methamphetamine and its analogs. NIDA Res. Monogr., 1991, 115, 109-120.
6. Dluzen, D.E.; Liu, B. Gender differences in methamphetamine use and responses: a review. Gend. Med., 2008, 5, 24-35.
7. Miller D.B.; O'Callaghan, J.P. The role of temperature, stress and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol. Neurobiol., 1995, 11, 177-192.
8. Dluzen, D.E.; McDermott, J.L. Estrogen, anti-estrogen, and gender differences in methamphetamine neurotoxicity. Ann. NY Acad. Sci., 2002, 965, 136-156.
9. van Harmelen, V.; Wahrenberg, H.; Erikson P.; Arner, P. Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue. Thromb. Haemost., 2000, 83, 304-308.
10. Asselbergs, F.W.; Williams, S.M.; Herbert, P.R.; Coffey, C.S.; Hillege, H.L.; Navis, G.; Vaughan, D.E.; Van Gilst, W.H.; Moore, J.H. Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plaminogen activator levels levels with cardiovascular disease-related traits. J. Thromb. Haemost., 2007, 5, 313-320.
11. Nagai, T.; Kamei, H.; Ito, H.M.; Hashimoto, K.; Takuma, K.; Nabeshima, T.; Yamada, K. Modification by the tissue plasminogen activator-plasmin system of morphine-induced dopamine release and hyperlocomotion, buy not anti-nociceptive effect in mice. J. Neurochem., 2005, 93, 1272-1279.
12. Rodriquez-Navarro, J.A.; Solano, R.M.; Casarejos, M.J.; Gomez, A.; Perucho, J.; Garcia de Yebenes, J.; Mena, M.A. Gender differences and estrogen effects in parkin null mice. J. Neurochem., 2008, 106, 2143-2157.
13. Imam, S. Z.; Itzhak, Y.; Cadet, J.L.; Islam F.; Slikker Jr., W.; Ali, S.F. Methamphetamine-induced alteration in p53 and bcl-2 expression in mice. Mol. Brain Res., 2001, 91, 174-178.
14. Deng, X.; Cai, N.S.; McCoy, M.T.; Chen, W.; Trush, M.A.; Cadet, J.L. Methamphetamine induces apoptosis in an immortalized rat striatal cell line by activating the mitochondrial cell death pathway. Neuropharmacology, 2002, 42, 837-845.
15. Cadet, J.L.; Ordonez, S.V.; Ordonez, J.V. Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto-oncogene, bcl-2. Synapse, 1997, 25, 176-184.
16. Bourque M.; Dluzen, D.E.; Di Paolo, T. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol., 2009, 30, 142-157.
17. Bhatt, S.D.; Dluzen, D.E. Dopamine transporter function differences between male and female CD-1 mice. Brain Res., 2005, 1035, 188-195.
18. Morissette, M.; Di Paolo, T. Sex and estrous cycle variations of striatal dopamine uptake sites. Neuroendocrinology, 1993, 58, 16-22.
19. Lavalaye, J.; Booji, J.; Reneman, L.; Harbraken, J. B.; von Royen, E.A. Effect of age and gender on dopamine transporter imaging with [123I] FP-CIT SPET in healthy volunteers. Eur. J. Nucl. Med., 2000, 27, 867-879.
20. Ji, J.; Bourque, M.; Di Paolo, T.; Dluzen, D.E. Genetic alteration in the dopamine transporter differentially affects male and female nigrostriatal transporter systems. Biochem. Pharmacol., 2009, 78, 1401-1411.
21. Ji J.; Dluzen, D.E. Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice. J. Neural Transm., 2008, 115, 809-817.